<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676270</url>
  </required_header>
  <id_info>
    <org_study_id>IB-2018Phase I</org_study_id>
    <nct_id>NCT03676270</nct_id>
  </id_info>
  <brief_title>Trends in Modern Phase 1 Oncology Trials</brief_title>
  <acronym>Phase 1</acronym>
  <official_title>Trends in Modern Phase 1 Oncology Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overview of response rate published in recent oncology phase I trials&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critics have raised a fundamental ethical challenge about phase 1 cancer research. They point&#xD;
      to an expected paucity of benefits, since approximately 5% of patients in phase 1 trials are&#xD;
      reported to have tumor shrinkage.&#xD;
&#xD;
      Objective was to conduct a search of the literature using PubMed to identify articles about&#xD;
      phase 1 trials that were published from January 1, 2014, through June 30, 2015. The primary&#xD;
      end point was the response rate according to Response Evaluation Criteria in Solid Tumors&#xD;
      (RECIST) criteria.&#xD;
&#xD;
      Clinically relevant trials' characteristics were investigated as candidate factors associated&#xD;
      with the RR: Funding source (Academic / Industrial), First-in man trial (Yes / No), Expansion&#xD;
      cohort (Yes / No), Number of targeted organs (Single / Multiple), Therapy (Single /&#xD;
      Combination), Treatment (MAB-Immuno / ITK / Chimioth-HT-other), Biological eligibility&#xD;
      criterion (Yes / No), as well as the number of assessable patients, which for ease of&#xD;
      clinical interpretation was transformed into a qualitative variable (0-25 / 26 - 50 / 51+).&#xD;
&#xD;
      The RR was described according to the individual trials' characteristics. Associations with&#xD;
      trials's characteristics were investigated using statistical modeling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>up to 6 months after treatment initiation</time_frame>
    <description>Number of reported responses (complete [CR] and partial [PR]) divided by the number of reported assessable patients</description>
  </primary_outcome>
  <enrollment type="Actual">6915</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phase I</intervention_name>
    <description>Chemotherapy, ITK, Hormotherapy, Immunotherapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        unit of analysis = trial (analysis of aggregated data only, with the trial as the unit of&#xD;
        analysis)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Trials based on the following eligibility criteria:&#xD;
&#xD;
          -  cancer phase 1 trials&#xD;
&#xD;
          -  published from January 1, 2014, through June 30, 2015&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Italiano, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Insitut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Chakiba C, Grellety T, Bellera C, Italiano A. Encouraging Trends in Modern Phase 1 Oncology Trials. N Engl J Med. 2018 Jun 7;378(23):2242-2243. doi: 10.1056/NEJMc1803837.</citation>
    <PMID>29874526</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <results_first_submitted>December 8, 2020</results_first_submitted>
  <results_first_submitted_qc>January 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2021</results_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Phase I trials</keyword>
  <keyword>Review</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>224 trials were analyzed which included 6915 participants</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Participants Included in Phase 1 Oncology Trials</title>
          <description>Participants included in Phase 1 Oncology Trials, published from January 1, 2014, through June 30, 2015.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6915"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6915"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trials</title>
          <description>Cancer Phase 1 trials</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6915"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>trials with participant &gt; 18 years old</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6915"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6915"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3458"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Number of reported responses (complete [CR] and partial [PR]) divided by the number of reported assessable patients</description>
        <time_frame>up to 6 months after treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Oncology Trials</title>
            <description>Phase 1 Oncology Trials, published from January 1, 2014, through June 30, 2015.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Number of reported responses (complete [CR] and partial [PR]) divided by the number of reported assessable patients</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6915"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed</time_frame>
      <desc>All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Participants Included in Phase 1 Oncology Trials</title>
          <description>Participants included in Phase 1 Oncology Trials, published from January 1, 2014, through June 30, 2015.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr Antoine Italiano</name_or_title>
      <organization>Institut Bergonié</organization>
      <phone>335 56333333</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

